184 related articles for article (PubMed ID: 8142644)
21. Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Gibson AD
Clin Lymphoma; 2002 Jun; 3(1):18-9. PubMed ID: 12141950
[No Abstract] [Full Text] [Related]
22. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody.
Co MS; Scheinberg DA; Avdalovic NM; McGraw K; Vasquez M; Caron PC; Queen C
Mol Immunol; 1993 Oct; 30(15):1361-7. PubMed ID: 8232322
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.
Scheinberg DA; Tanimoto M; McKenzie S; Strife A; Old LJ; Clarkson BD
Leukemia; 1989 Jun; 3(6):440-5. PubMed ID: 2725060
[TBL] [Abstract][Full Text] [Related]
24. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.
Xu Y; Scheinberg DA
Clin Cancer Res; 1995 Oct; 1(10):1179-87. PubMed ID: 9815910
[TBL] [Abstract][Full Text] [Related]
25. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Sievers EL; Appelbaum FR; Spielberger RT; Forman SJ; Flowers D; Smith FO; Shannon-Dorcy K; Berger MS; Bernstein ID
Blood; 1999 Jun; 93(11):3678-84. PubMed ID: 10339474
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
Borthakur G; Rosenblum MG; Talpaz M; Daver N; Ravandi F; Faderl S; Freireich EJ; Kadia T; Garcia-Manero G; Kantarjian H; Cortes JE
Haematologica; 2013 Feb; 98(2):217-21. PubMed ID: 22875630
[TBL] [Abstract][Full Text] [Related]
27. Antibody-targeted therapy for myeloid leukemia.
Appelbaum FR
Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
29. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
[TBL] [Abstract][Full Text] [Related]
31. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
33. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
Appelbaum FR; Matthews DC; Eary JF; Badger CC; Kellogg M; Press OW; Martin PJ; Fisher DR; Nelp WB; Thomas ED
Transplantation; 1992 Nov; 54(5):829-33. PubMed ID: 1440849
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
35. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
Raza A; Jurcic JG; Roboz GJ; Maris M; Stephenson JJ; Wood BL; Feldman EJ; Galili N; Grove LE; Drachman JG; Sievers EL
Leuk Lymphoma; 2009 Aug; 50(8):1336-44. PubMed ID: 19557623
[TBL] [Abstract][Full Text] [Related]
36. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice.
Namikawa R; Ueda R; Kyoizumi S
Blood; 1993 Oct; 82(8):2526-36. PubMed ID: 8104540
[TBL] [Abstract][Full Text] [Related]
37. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
38. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates.
Sievers EL
Curr Opin Oncol; 2000 Jan; 12(1):30-5. PubMed ID: 10687726
[TBL] [Abstract][Full Text] [Related]
39. [Monoclonal antibody therapies for acute leukemia].
Takeshita A; Ono R
Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
[No Abstract] [Full Text] [Related]
40. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Bernstein ID
Leukemia; 2000 Mar; 14(3):474-5. PubMed ID: 10720144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
